SCHEMBL3910274

SCHEMBL3910274

CC(C)(C)OC(=O)N1CCN(S(=O)(=O)c2ccc(I)cc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 12/20 0.64
▸ F13A1 P00488 9/20 0.64
▸ TGM1 P22735 6/20 0.64
▸ PKM P14618 2/20 0.54
▸ STS P08842 1/20 0.54
▸ POLB P06746 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ GPR119 Q8TDV5 1/20 0.50
▸ TGM3 Q08188 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18410584 0.88 TGM2 (0.65) TGM2F13A1TGM1PKMPOLB
SCHEMBL5253160 0.86 POLB (0.70) TGM2F13A1TGM1STSPOLB
SCHEMBL29060791 0.86 TGM2 (0.64) TGM2F13A1TGM1PKMPOLB
SCHEMBL710366 0.86 TGM2 (0.64) TGM2F13A1TGM1PKM
SCHEMBL1181084 0.86 PKM (0.73) TGM2F13A1TGM1PKM
SCHEMBL1684972 0.86 TGM2 (0.69) TGM2F13A1TGM1PKMSTS
SCHEMBL27200534 0.86 TGM2 (0.64) TGM2F13A1TGM1PKMSTS
SCHEMBL2252120 0.86 TGM2 (0.63) TGM2F13A1TGM1GPR119
SCHEMBL1253831 0.85 TGM2 (0.63) TGM2F13A1TGM1PKMSTS
SCHEMBL18153290 0.85 PKM (0.66) TGM2F13A1TGM1PKMSTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436667-B1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2026-01-21 — — EP disclosed
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2025-01-09 — — US disclosed
US-20240417387-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2024-12-19 — — US disclosed
EP-4436667-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2024-10-02 — — EP disclosed
CN-118201916-A Piperazinylsulfonylaryl compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-06-14 — — CN disclosed
CN-118076594-A Sulfonylpiperazinyl compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-05-24 — — CN disclosed
WO-2023072794-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-05-04 — — WO disclosed
WO-2023061617-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 — — WO disclosed
EP-0976722-B1 BENZAMIDINE DERIVATIVES AJINOMOTO KK (JP) 2009-03-11 — — EP disclosed
US-7396844-B1 Benzamidine derivatives AJINOMOTO CO., INC. (JP) 2008-07-08 — — US disclosed
EP-0976722-A1 BENZAMIDINE DERIVATIVES Ajinomoto Co., Inc. (JP) 2000-02-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS ABL1, Q6ZSR9, NQO2 TGM2 3212/4885F13A1 4046/4885TGM1 1128/4885
US-20240417387-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS CFTR, KCNQ1, Q6ZSR9 TGM2 3759/4885F13A1 3038/4885TGM1 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback